Jazz Pharmaceuticals plc's (JAZZ) CEO Bruce Cozadd on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/03/20
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/26/20
Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with NarcolepsyPRNewsWire • 10/20/20
Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020PRNewsWire • 10/19/20
Jazz Stock Returns To Buy Zone After Company Posts Positive Drug Trial DataInvestors Business Daily • 10/08/20
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic HypersomniaPRNewsWire • 10/08/20
Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative StrengthInvestors Business Daily • 09/24/20
Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of LeukemiaPRNewsWire • 09/17/20
Cleave Therapeutics Announces Preclinical Research Collaboration With Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)Business Wire • 09/09/20
Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer TherapiesPRNewsWire • 09/09/20
Jazz Pharmaceuticals Announces Participation at Three Upcoming Virtual Investor ConferencesPRNewsWire • 09/08/20
Jazz (JAZZ) Up 11.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/03/20